久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Kineta Announces First Participant Dosed in KCP506 Trial for Chronic Pain americanpharmaceuticalreview
    December 17, 2020
    Kineta, through its subsidiary Kineta Chronic Pain LLC, announced the first participant has been successfully dosed in a Phase 1 clinical trial of KCP506, an investigational, first-in-class α9/α10 nicotinic acetylcholine receptor (nAChR) antagonist in ...
  • Kineta Receives Regulatory Approval for Initiation of KCP506 Trial americanpharmaceuticalreview
    August 18, 2020
    Kineta announced the Clinical Trial Application (CTA) approval in the Netherlands for initiation of a first in-human clinical trial of KCP506. KCP506 is a first-in-class α9α10 nicotinic acetylcholine receptor (nAChR) antagonist in development for the ...
PharmaSources Customer Service